AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating restated by research analysts at J P Morgan Chase & Co in a report released on Friday.

Other equities analysts have also recently issued reports about the company. Deutsche Bank AG reaffirmed a “buy” rating and issued a GBX 5,700 ($74.97) price objective on shares of AstraZeneca plc in a report on Friday, July 28th. Kepler Capital Markets reaffirmed a “buy” rating and issued a GBX 5,500 ($72.34) price objective on shares of AstraZeneca plc in a report on Thursday, July 13th. Liberum Capital reaffirmed a “buy” rating and issued a GBX 5,500 ($72.34) price objective on shares of AstraZeneca plc in a report on Thursday, July 13th. Citigroup Inc. reaffirmed a “buy” rating and issued a GBX 6,000 ($78.92) price objective on shares of AstraZeneca plc in a report on Thursday, July 13th. Finally, Berenberg Bank set a GBX 5,500 ($72.34) price objective on AstraZeneca plc and gave the company a “buy” rating in a report on Friday, July 28th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of GBX 5,247.18 ($69.01).

AstraZeneca plc (LON:AZN) opened at GBX 4,870 ($64.05) on Friday. AstraZeneca plc has a fifty-two week low of GBX 3,996 ($52.56) and a fifty-two week high of GBX 5,520 ($72.60).

WARNING: “AstraZeneca plc (AZN) Rating Reiterated by J P Morgan Chase & Co” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/astrazeneca-plc-azn-rating-reiterated-by-j-p-morgan-chase-co/1697490.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.